Evolent Health Inc (EVH) Given Consensus Rating of “Buy” by Analysts

Evolent Health Inc (NYSE:EVH) has been given an average recommendation of “Buy” by the seventeen ratings firms that are currently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and thirteen have given a buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $27.78.

Several equities research analysts have weighed in on the company. Zacks Investment Research raised Evolent Health from a “sell” rating to a “hold” rating in a report on Monday, October 9th. Citigroup assumed coverage on Evolent Health in a report on Thursday, January 4th. They issued a “buy” rating for the company. Canaccord Genuity reissued a “buy” rating and issued a $32.00 price target on shares of Evolent Health in a report on Friday, October 6th. Goldman Sachs Group downgraded Evolent Health from a “conviction-buy” rating to a “buy” rating in a report on Tuesday, November 7th. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $30.00 price target on shares of Evolent Health in a report on Thursday, November 2nd.

Several institutional investors have recently added to or reduced their stakes in EVH. FMR LLC lifted its holdings in shares of Evolent Health by 117.7% during the second quarter. FMR LLC now owns 9,864,775 shares of the technology company’s stock worth $250,073,000 after purchasing an additional 5,333,252 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Evolent Health by 37.3% during the third quarter. JPMorgan Chase & Co. now owns 7,465,019 shares of the technology company’s stock worth $136,236,000 after purchasing an additional 2,026,893 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Evolent Health by 48.9% during the second quarter. Vanguard Group Inc. now owns 3,769,869 shares of the technology company’s stock worth $95,566,000 after purchasing an additional 1,237,941 shares during the period. Kornitzer Capital Management Inc. KS acquired a new stake in shares of Evolent Health during the third quarter worth about $14,258,000. Finally, Jennison Associates LLC acquired a new stake in shares of Evolent Health during the third quarter worth about $12,531,000. 95.42% of the stock is owned by hedge funds and other institutional investors.

Shares of Evolent Health (EVH) opened at $14.65 on Friday. The company has a quick ratio of 3.34, a current ratio of 3.34 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $1,105.91, a PE ratio of -12.96 and a beta of 1.07. Evolent Health has a twelve month low of $10.30 and a twelve month high of $27.50.

Evolent Health (NYSE:EVH) last issued its quarterly earnings results on Thursday, November 2nd. The technology company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.04. The business had revenue of $107.90 million during the quarter, compared to the consensus estimate of $104.49 million. Evolent Health had a negative return on equity of 5.05% and a negative net margin of 15.86%. The company’s quarterly revenue was up 79.2% on a year-over-year basis. During the same quarter last year, the company earned ($0.26) earnings per share. sell-side analysts forecast that Evolent Health will post -0.57 EPS for the current year.

WARNING: “Evolent Health Inc (EVH) Given Consensus Rating of “Buy” by Analysts” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/01/27/evolent-health-inc-evh-given-consensus-rating-of-buy-by-analysts.html.

Evolent Health Company Profile

Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.

Analyst Recommendations for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply